Faeth Therapeutics (FTH) Income from Continuing Operations (2020 - 2026)

Faeth Therapeutics (FTH) has 7 years of Income from Continuing Operations data on file, last reported at 182389000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 2378.78% year-over-year to 182389000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 200113000.0 (down 446.53% YoY) and the FY2025 annual result came in at 81845000.0, up 7.25% from the prior year.
• Income from Continuing Operations eased to 182389000.0 in Q1 2026, from 3446000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 3446000.0 in Q4 2025 to a low of 182389000.0 in Q1 2026.
• A 5-year average of 20180000.0 and a median of 11197000.0 in 2022 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 57.83% — and 2026, when it tumbled 2378.78%.
• Tracing FTH's Income from Continuing Operations over 5 years: stood at 12233000.0 in 2022, then soared by 44.54% to 6784000.0 in 2023, then increased by 12.09% to 5964000.0 in 2024, then surged by 42.22% to 3446000.0 in 2025, then tumbled by 5192.77% to 182389000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 182389000.0 (Q1 2026), 3446000.0 (Q4 2025), and 6743000.0 (Q3 2025), per Business Quant data.